"The Sanford Project: T-Rex Study", a collaborative study between Sanford Health and Caladrius Biosciences, Inc., for adolescents with newly onset type 1 diabetes has examined the body's ability to type fight 1 diabetes using cell therapy on its first participant.
Type 1 diabetes, an autoimmune disease characterized by a loss of insulin-producing beta cells, is the focus of The Sanford Project, a cornerstone research initiative at Sanford Research.
Investigators in this trial are studying the effectiveness of cell therapy with expanded regulatory T cells, or Treg cells, to treat type 1 diabetes. Treg cells regulate the body's immune system. A participant's own Treg cells are extracted from the body, purified and multiplied and returned to blood circulation. Researchers are monitoring if beta cells and insulin production can be preserved through this type of immunotherapy.
Participants in The Sanford Project: T-Rex Study must be 12 to 17 years old and have been diagnosed with diabetes in approximately the last two months.